Gene therapy company Oxford Biomedica expects five clinical trials to be under way by the end of this year. The firm, an Oxford University spin-out based at Oxford Science Park, said work on its new £2.2m laboratory at Cowley, is on track to open in the first half of 2012. Treatment of all six patients in a trial of its experimental Parkinson’s Disease, ProSavin, has been completed, and the company said its gene-based therapies for eye disease were also progressing.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here